CPHI Frankfurt 2025: Getting the Balance between Cost and Productivity Right with Innovation

As geopolitical factors are driving a greater focus on U.S. manufacturing, many companies are seeking ways to improve productivity while keeping their products affordable for patients, highlights Russell Miller from Enzene.

Two years ago, the Biosecure Act was a key discussion point for industry, with many stakeholders wondering how buying behaviors may change, reveals Russell Miller, Vice President, Global Sales and Marketing at Enzene. “The message that we, at Enzene, shared at that time was that the Biosecure Act just opened up dialogue in areas that we might not have had previously,” he notes. “Looking at what is happening today with the immediacy of the impact of things like tariffs, it is really accelerating conversations that would have never taken place.”

For example, Miller continues, recent conversations with customers have been centered around options for commercial manufacturing and tech transfer in the U.S. whereby affordability can still be maintained. “So, in this current instance of geopolitical [change, there has been] a lot more interest in how folks can access drug substance manufacturing in the U.S.,” he says.

There are really two routes open to customers to access manufacturing in the U.S., either the traditional approach or utilizing innovative technologies, Miller points out. “At first blush, a lot of these clients, they’re really looking just for tech transfer — they want to get their product into a place where they can still maintain supply chain and access for patients without adding more risk,” he states.

“[However,] there are multiple countries around the world where folks are focused on patient affordability and patient access,” Miller adds. Within such locations there may be policies in place that means the cost of a therapy to a patient is limited, and this is where innovative technologies, such as EnzeneX can help, he reveals.

Utilizing innovative technologies, such as EnzeneX, means that companies can increase their productivity while also reducing cost of goods, Miller points out. Such benefits make a compelling case for companies to evaluate innovative technologies and, as a result, assess ways to integrate it into their development process, he adds.

While innovative technologies are exciting, it is prudent to remember that the bio/pharma industry is a highly regulated one and there is a potential risk to implementing these new tools, Miller warns. “So, in [Enzene’s] strategic plan, we have the design matrix where we are going to integrate all the elements that the FDA would like to see in a continuous process so that the EnzeneX platform is ready to be approved,” he notes.

Click the video above to view the full interview

Enzene can be found in Hall 5.0 Booth #A68 at CPHI Frankfurt.

*EnzeneX is a registered trademark of Enzene.

About the Speaker

Russell Miller is the Vice President, Global Sales and Marketing at Enzene. Russell is a results-oriented business development leader with over two decades of experience driving growth in the pharmaceutical and biotech industries. His expertise spans analytical services, formulation development, and manufacturing, providing him with a deep understanding of the drug development process.

Spending over a decade at Catalent Pharma Solutions, he consistently exceeded sales targets and spearheaded strategic initiatives, including the successful reinvigoration of sales in the Northeast region and the design and implementation of a global Inside Sales Group. He has also held leadership roles at Vectura, ANI Pharmaceuticals, and Scotwork, consistently demonstrating his ability to establish companies as leading CDMOs, reinvigorate sales funnels, and streamline operations.

At Enzene, Russell's focus is on forging strategic partnerships and delivering solutions that exceed expectations, driving the company's continued success.

Music from #Uppbeat (free for Creators!):
https://uppbeat.io/t/richard-smithson/air  
License code: QHDAN9DIKVMQW8EK

Image Credit: © allvision - stock.adobe.com